This marks the latest integration of Dexcom’s next-generation CGM into automated insulin delivery technology. Omnipod 5, Insulet’s newest patch pump offering, previously worked with the G6 in the U.S. It also recently integrated the system with Abbott’s FreeStyle Libre 2 Plus in Europe.
Insulet previously suggested that G7 integration would come early in 2024. In the company’s fourth-quarter earnings report yesterday evening — which included Street-beating results — the company confirmed the initial limited rollout began recently.
By the middle of the next day, PODD shares were down more than 4% to $187.81 apiece. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.
BTIG analysts Marie Thibault and Sam Eiber suggested that the initial investor reaction may be related to changes in the company’s order timing reporting. However, the underlying numbers remain strong.
Get the full story at our sister site, Drug Delivery Business News.
This story originally ran on Feb. 22, 2024. Updated Feb. 23 with next-day stock price.